In a report released today, David Adlington from J.P. Morgan maintained a Buy rating on Siemens Healthineers AG (SEMHF – Research Report), with a price target of EUR62.10. The company’s shares closed yesterday at $53.45.
Adlington covers the Healthcare sector, focusing on stocks such as Siemens Healthineers AG, Koninklijke Philips, and Alcon. According to TipRanks, Adlington has an average return of -3.5% and a 40.24% success rate on recommended stocks.
Currently, the analyst consensus on Siemens Healthineers AG is a Strong Buy with an average price target of $63.10, representing a 18.05% upside. In a report released on January 10, Barclays also maintained a Buy rating on the stock with a EUR63.00 price target.
See the top stocks recommended by analysts >>
SEMHF market cap is currently $57.42B and has a P/E ratio of 27.27.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SEMHF in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Siemens Healthineers AG operates as a holding company. The company intends to operate the digital services business. It operates through the following business segments: Imaging, Diagnotics, and Advanced Therapies. The Imaging segment offers diagnostic imaging products and a broad portfolio of advanced imaging and ultrasound systems and solutions. The Diagnostics segment offers products, services and solutions, including a broad array of testing applications, in the areas of laboratory, point of care and molecular diagnostics. The Advanced Therapies is a supplier of advanced therapy products, services and solutions to the therapy departments of healthcare providers. Siemens Healthineers was founded on December 1, 2017 and is headquartered in Erlangen, Germany.
